Guanfacine

Generic Name
Guanfacine
Brand Names
Intuniv, Tenex
Drug Type
Small Molecule
Chemical Formula
C9H9Cl2N3O
CAS Number
29110-47-2
Unique Ingredient Identifier
30OMY4G3MK
Background

Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.

Guanfacine was granted FDA approval on 27 October 1986.

Indication

Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
Associated Therapies
-
Clinical Trials
Related News

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

First Posted Date
2014-10-08
Last Posted Date
2023-02-02
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
38
Registration Number
NCT02259517
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)

Not Applicable
Active, not recruiting
Conditions
Chronic Pain
Interventions
Drug: Guanfacine
Drug: Placebo
First Posted Date
2014-07-16
Last Posted Date
2024-01-05
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
120
Registration Number
NCT02192398
Locations
🇺🇸

MGH Center for Translational Pain Research, Boston, Massachusetts, United States

Guanfacine Clinical Trial for Smoking Cessation

Phase 2
Completed
Conditions
Smoking Cessation
Interventions
Drug: Placebo
Drug: Guanfacine
First Posted Date
2014-01-31
Last Posted Date
2021-12-29
Lead Sponsor
Yale University
Target Recruit Count
121
Registration Number
NCT02051309
Locations
🇺🇸

Yale Center for Clinical Investigations, Yale University, New Haven, Connecticut, United States

PK/PD Comparison of Guanfacine ER and IR

Phase 2
Completed
Conditions
Smoking
Interventions
Drug: Guanfacine
First Posted Date
2013-07-22
Last Posted Date
2020-03-06
Lead Sponsor
Yale University
Target Recruit Count
5
Registration Number
NCT01904526
Locations
🇺🇸

Yale Center for Clinical Investigations, Yale University, New Haven, Connecticut, United States

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects

Not Applicable
Completed
Conditions
NMDA Receptor Function
Interventions
Drug: Guanfacine
Drug: Placebo
First Posted Date
2012-05-17
Last Posted Date
2017-08-21
Lead Sponsor
Yale University
Target Recruit Count
16
Registration Number
NCT01600885
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

🇺🇸

Yale Magnetic Resonance Research Center, New Haven, Connecticut, United States

🇺🇸

Veterans Affairs Hospital, West Haven, Connecticut, United States

Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence

Phase 1
Completed
Conditions
Cannabis Dependence
Interventions
Drug: Guanfacine
First Posted Date
2011-11-09
Last Posted Date
2019-02-05
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
22
Registration Number
NCT01467999
Locations
🇺🇸

STARS, New York, New York, United States

Interventions for Children With Attention and Reading Disorders

First Posted Date
2010-05-31
Last Posted Date
2017-04-11
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
222
Registration Number
NCT01133847
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

University of Texas Health Science Center, Houston, Texas, United States

Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance

Phase 2
Completed
Conditions
Stroke
Hemispatial Neglect
Interventions
Drug: Guanfacine
Drug: Placebo
First Posted Date
2009-08-10
Last Posted Date
2020-01-21
Lead Sponsor
Imperial College London
Target Recruit Count
13
Registration Number
NCT00955253
Locations
🇬🇧

Imperial College Healthcare NHS Trust, London, United Kingdom

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

Not Applicable
Completed
Conditions
Cognitive Aging
Interventions
Drug: Guanfacine
Drug: Placebo
First Posted Date
2009-07-09
Last Posted Date
2014-08-13
Lead Sponsor
Yale University
Target Recruit Count
154
Registration Number
NCT00935493
Locations
🇺🇸

Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, United States

Modeling Stress-precipitated Smoking Behavior for Medication Development

Phase 2
Completed
Conditions
Smoking
Interventions
Drug: guanfacine
Drug: placebo
First Posted Date
2008-10-16
Last Posted Date
2022-08-03
Lead Sponsor
Yale University
Target Recruit Count
100
Registration Number
NCT00773357
Locations
🇺🇸

Yale Center for Clinical Investigation, Yale University, New Haven, Connecticut, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy